Opportunities to Optimize Cancer Policies Panel Discussion

First International Summit on Interventional Pharmacoeconomics

Mark J. Ratain, MD, on Chronic Lymphocytic Leukemia: Making a Case for Low-Dose Ibrutinib

Mark J. Ratain, MD, of the University of Chicago, talks about why ibrutinib—which can lead to cardiotoxicities—should be studied at a lower dose for patients with chronic lymphocytic leukemia. Data suggest a reduced dose may prevent dose interruption due to adverse events and may have a better therapeutic index.

S. Vincent Rajkumar, MD, on Cost-Effective Treatment of Multiple Myeloma

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Amit Sanyal, MD: A Clinician’s Perspective

Blase Polite, MD, MPP, FASCO, on Transforming the Drug Cost Curve in the United States: Not How But If

Nov

Today In Oncology

Opportunities to Optimize Cancer Policies Panel Discussion

Related Videos

Mark J. Ratain, MD, on Chronic Lymphocytic Leukemia: Making a Case for Low-Dose Ibrutinib

S. Vincent Rajkumar, MD, on Cost-Effective Treatment of Multiple Myeloma

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Amit Sanyal, MD: A Clinician’s Perspective

Blase Polite, MD, MPP, FASCO, on Transforming the Drug Cost Curve in the United States: Not How But If

FDA Approves Ziftomenib for NPM1-Positive AML

Neoadjuvant Dual ICI Blockade vs Perioperative FLOT in dMMR/MSI-H Gastroesophageal Adenocarcinoma

Final Overall Survival Confirms Benefit of Durvalumab Plus FLOT in Resectable Gastric and Gastroesophageal Junction Adenocarcinomas

Ezabenlimab, Induction Chemotherapy, and Adaptive Chemoradiotherapy in Stage III Squamous Cell Anal Carcinoma

Transfusion Access Prioritized Over Routine Hospice Services Among Patients With Blood Cancers